Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year
Publishing timestamp: 2024-06-21 16:29:35
Summary
Eli Lilly has applied for U.S. approval of its weight loss drug Zepbound for the treatment of obstructive sleep apnea. Additional data from late-stage trials showed promising results, adding to the growing evidence of health benefits tied to weight loss and diabetes treatments. If approved, the company plans to launch Zepbound in early 2025.
Sentiment: POSITIVE
Tickers: LLY,
Keywords: business, biotech and pharmaceuticals, pharmaceuticals, biotechnology, science, business news, eli lilly and co, health care industry,